{"filing":{"accession_number":"0001628280-26-040225","cik":"0001933414","ticker":"MLYS","company_name":"Mineralys Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-03","report_date":null,"primary_document":"mlys-20260603.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1933414/000162828026040225/mlys-20260603.htm"},"events":[{"id":7296,"run_id":6405,"accession_number":"0001628280-26-040225","anchor_item_number":"8.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Mineralys entered into an underwriting agreement on June 3, 2026 to issue 5,660,378 shares of common stock at $26.50 per share, with expected net proceeds of approximately $142.5 million. This is a registered public offering of equity securities that will dilute existing shareholders. The disclosure of the underwriting agreement, pricing, and expected closing date constitutes a material dilutive issuance event requiring 8-K disclosure under Item 3.02 (though filed under Item 8.01).","company_name":"Mineralys Therapeutics, Inc.","ticker":"MLYS","filing_date":"2026-06-03","form":"8-K","submitted_at":null,"items":[{"id":4132,"accession_number":"0001628280-26-040225","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Mineralys entered into an underwriting agreement on June 3, 2026 to issue 5,660,378 shares of common stock at $26.50 per share, with expected net proceeds of approximately $142.5 million. This is a registered public offering of equity securities that will dilute existing shareholders. The disclosure of the underwriting agreement, pricing, and expected closing date constitutes a material dilutive issuance event requiring 8-K disclosure under Item 3.02 (though filed under Item 8.01).","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:49:46.360927+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4132,"accession_number":"0001628280-26-040225","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Mineralys entered into an underwriting agreement on June 3, 2026 to issue 5,660,378 shares of common stock at $26.50 per share, with expected net proceeds of approximately $142.5 million. This is a registered public offering of equity securities that will dilute existing shareholders. The disclosure of the underwriting agreement, pricing, and expected closing date constitutes a material dilutive issuance event requiring 8-K disclosure under Item 3.02 (though filed under Item 8.01).","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:49:46.360927+00:00","company_name":"Mineralys Therapeutics, Inc.","ticker":"MLYS","filing_date":"2026-06-03"}]}